Sitasentan TBC 11251
Sitasentan,TBC 11251
210421-64-0
N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH).[1] It was marketed as Thelin by Encysive Pharmaceuticals until Pfizerpurchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan…
